Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.
about
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesWarfarin reversalAn in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starchReversal of oral anticoagulationRational Use of Recombinant Factor VIIa in Clinical PracticeUrgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?The use of recombinant activated coagulation factor VII for spine surgeryTransfusion medicine service policies for recombinant factor VIIa administration.Recombinant factor VIIa.Recombinant activated factor VII in patients at high risk of bleeding.Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins.Pharmacology and clinical use of recombinant activated factor seven in neurosciences.Percutaneous interventions in the coagulopathic patient.Correction of coagulopathy for percutaneous interventions.The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage.Polyphosphate as a general procoagulant agent.Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathyManagement of anticoagulant-related intracranial hemorrhage: an evidence-based review.Recombinant factor VIIa use in patients presenting with intracranial hemorrhage.Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study.Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settingsMethods for improved hemorrhage control.Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.Recombinant factor VIIa in the treatment of non-hemophiliac bleeding.The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.Trends in clinical toxicology: advances that may change your practice.Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhageRecombinant activated factor VIIa and hemostasis in critical care: a focus on traumaProposal for the Rapid Reversal of Coagulopathy in Patients with Nonoperative Head Injuries on Anticoagulants and/or Antiplatelet Agents: A Case Study and Literature Review.Management of bleeding emergencies: when to use recombinant activated factor VII.Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trialA critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.Perioperative management of patients receiving vitamin K antagonists.Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms.Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.Warfarin reversal in anticoagulant-associated intracerebral hemorrhage.Formulary management of recombinant factor VIIa at an academic medical center.Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice.Management of surgical patients receiving anticoagulation and antiplatelet agents.
P2860
Q24632951-AC003A25-A719-4856-AA51-3300292FC5B0Q24672566-4D9B674E-1E16-4ED1-BF8A-0F97B03559E8Q24797362-3F7F079C-39D5-4244-8A83-A97598099CEFQ26827835-DB7EF0A0-EEE8-4AAC-B344-33D1F2B950D8Q26829915-EADF9BC9-4A89-419E-9A4B-EE786CACD75EQ31040247-F0D9FEFC-D389-40C0-A9F1-D0A632265DD5Q33360946-54C2693B-B8EE-4B5A-8155-67F7D7586338Q33362187-1DF193A1-CABD-4BA2-A64A-C7982AFAC7C7Q33363658-27B97B0B-324D-41F4-81C3-49023FDFC112Q33365354-6B1F34DA-B6FF-421F-8940-9614F0391825Q33370419-FE2FB254-3FF3-47C0-B6D5-7DC337B28FBFQ33375346-5C5928F9-1F24-4422-865E-8E61BC42CA08Q33394177-38EA7AFD-AA40-4742-B943-5C54F00615FBQ33401040-2DCB41CB-3AD8-4D88-9752-89DB49374B66Q33549913-A0D973B1-C852-440F-9985-C168A2C1FC0CQ33724794-1E58270B-8F0C-46C6-94FA-8BABCAAAE19AQ33735132-BA8E23BC-DB3D-4DE0-8A6E-EB7C4F3EB1E1Q33750215-9E03247D-9716-400A-B031-3BD82E07E467Q34135771-7B001CDF-B8CD-4E6B-BA77-7F31507F58EDQ34469002-F4627D6B-CA38-4F56-8925-803FEB101E07Q34513276-2D1C0313-03C8-40C7-90F2-24307EE73B74Q35578941-BE4D94BD-853C-4553-B27C-14E54A01FE1EQ35578975-8168EB2A-5953-4C62-8A07-C99D31E03BDEQ35879063-17D7D87E-9339-4A22-B132-48E18AFE9C90Q36077574-40976639-5FAC-4887-B008-272184CCB49AQ36150578-354C2E16-EEF6-4F17-A152-E4DAF2F85207Q36155920-6F9A7848-1CE1-4197-8A0E-F26E813565CDQ36256080-42FF89E0-B375-4384-8A80-2FC4DB8E387AQ36284647-A981A1FE-792E-4630-BDC3-53167A579BDBQ36331578-8E3FB716-B1B5-48A5-8E86-DA7ACA2DD82CQ36349585-C14C1054-62D9-4D16-87B8-661FA66A9171Q36392691-3356102F-AE06-4108-A842-A891AE03D14BQ36462093-A762D40C-74AE-4AAA-811A-C7ECDC10F7EAQ36503057-EDA60827-C659-438A-A9AF-0EE4C517CC14Q36589312-950E45D9-7BE4-4D8F-A6FF-B8BCAC8F0F59Q36923137-78742CAA-0046-4068-8311-8A1186FEF6B7Q37063465-F1CACE3B-C96D-40C8-B489-CBF0E08FAB01Q37162880-4767F073-B808-4295-BB10-CCB1B164787EQ37210021-80E6766B-F05E-411F-9F06-E2F839471A92Q37320021-E5754704-CA80-4DF1-A87D-8462B1699A07
P2860
Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Reversal of warfarin-induced e ...... human factor VIIa concentrate.
@en
Reversal of warfarin-induced e ...... human factor VIIa concentrate.
@nl
type
label
Reversal of warfarin-induced e ...... human factor VIIa concentrate.
@en
Reversal of warfarin-induced e ...... human factor VIIa concentrate.
@nl
prefLabel
Reversal of warfarin-induced e ...... human factor VIIa concentrate.
@en
Reversal of warfarin-induced e ...... human factor VIIa concentrate.
@nl
P1476
Reversal of warfarin-induced e ...... human factor VIIa concentrate.
@en
P2093
Craig M Kessler
Ruby Anne E Deveras
P304
P356
10.7326/0003-4819-137-11-200212030-00009
P407
P577
2002-12-01T00:00:00Z